Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.

MLA

Van Neste, Leander, et al. “Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.” The Journal of Urology, vol. 211, no. 3, Mar. 2024, pp. 415–25. EBSCOhost, https://doi.org/10.1097/JU.0000000000003824.

APA

Van Neste, L., Henao, R., Wojno, K. J., Signes, J., DeHart, J., Busta, A., Marriott, E., Willing, M., Argentini, A., Hurley, P. M., Korman, H., Hafron, J., Putzi, M., Pieczonka, C. M., Karsh, L. I., Morris, D. S., Kassis, A. I., & Kantoff, P. W. (2024). Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification. The Journal of Urology, 211(3), 415–425. https://doi.org/10.1097/JU.0000000000003824

Chicago

Van Neste, Leander, Ricardo Henao, Kirk J Wojno, Jorge Signes, Jessica DeHart, Angela Busta, Elyse Marriott, et al. 2024. “Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.” The Journal of Urology 211 (3): 415–25. doi:10.1097/JU.0000000000003824.